• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抗血管生成治疗增强抗肿瘤免疫：肾癌的临床模型？

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

机构信息

Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

出版信息

Oncologist. 2019 Jun;24(6):725-727. doi: 10.1634/theoncologist.2019-0165. Epub 2019 Apr 29.

DOI:10.1634/theoncologist.2019-0165
PMID:31036769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6656499/
Abstract

Combination therapies involving antiangiogenic agents plus immune checkpoint inhibitors have recently demonstrated clinical efficacy in advanced renal cell carcinoma (RCC). This commentary summarizes the clinical advances and reviews the potential implications for RCC and other advanced solid tumors.

摘要

联合抗血管生成药物和免疫检查点抑制剂的治疗方案最近在晚期肾细胞癌（RCC）中显示出了临床疗效。本文总结了这些临床进展，并探讨了它们对 RCC 和其他晚期实体瘤的潜在影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad9b/6656499/8c387c51c9db/onco12956-fig-0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad9b/6656499/8c387c51c9db/onco12956-fig-0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad9b/6656499/8c387c51c9db/onco12956-fig-0001.jpg

相似文献

1
Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?抗血管生成治疗增强抗肿瘤免疫：肾癌的临床模型？
Oncologist. 2019 Jun;24(6):725-727. doi: 10.1634/theoncologist.2019-0165. Epub 2019 Apr 29.
2
Targeted therapy: An elusive cancer target.靶向治疗：一个难以捉摸的癌症靶点。
Nature. 2016 Sep 15;537(7620):S106-8. doi: 10.1038/537S106a.
3
Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma.贝伐单抗与免疫检查点抑制剂联合用于肾细胞癌
Cancer J. 2018 Jul/Aug;24(4):171-179. doi: 10.1097/PPO.0000000000000323.
4
Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.转移性肾细胞癌的系统治疗的测序和联合应用。
Eur Urol Oncol. 2019 Sep;2(5):505-514. doi: 10.1016/j.euo.2019.06.022. Epub 2019 Aug 1.
5
Targeting angiogenesis in metastatic renal cell carcinoma.针对转移性肾细胞癌的血管生成治疗。
Expert Rev Anticancer Ther. 2019 Mar;19(3):245-257. doi: 10.1080/14737140.2019.1574574. Epub 2019 Feb 6.
6
Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?转移性肾细胞癌的联合免疫疗法。我们是否有所遗漏？
Future Oncol. 2018 Dec;14(29):2997-2999. doi: 10.2217/fon-2018-0604. Epub 2018 Nov 9.
7
Combination therapy for renal cell cancer: what are possible options?肾癌的联合治疗：有哪些可能的选择？
Oncology. 2011;81(3-4):220-9. doi: 10.1159/000333470. Epub 2011 Nov 12.
8
Angiogenesis and angiogenic inhibitors in renal cell carcinoma.肾细胞癌中的血管生成与血管生成抑制剂
Curr Urol Rep. 2008 Jan;9(1):26-33. doi: 10.1007/s11934-008-0007-2.
9
Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials.晚期肾细胞癌患者接受免疫检查点抑制剂治疗的完全缓解：一项随机临床试验的荟萃分析。
Urol Oncol. 2020 Oct;38(10):798.e17-798.e24. doi: 10.1016/j.urolonc.2020.06.021. Epub 2020 Aug 7.
10
Systematic review on the efficacy and safety of immune checkpoint inhibition in renal cell carcinoma.免疫检查点抑制在肾细胞癌中的疗效和安全性的系统评价。
Future Oncol. 2018 Sep;14(21):2207-2221. doi: 10.2217/fon-2018-0193. Epub 2018 May 4.

引用本文的文献

1
Small molecule intervention of actin-binding protein profilin1 reduces tumor angiogenesis in renal cell carcinoma.肌动蛋白结合蛋白原肌球蛋白1的小分子干预可减少肾细胞癌中的肿瘤血管生成。
bioRxiv. 2025 Jul 21:2025.07.18.665115. doi: 10.1101/2025.07.18.665115.
2
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.通过联合靶向血管生成和PD-1/PD-L1通路增强抗癌免疫力：挑战与机遇
Front Immunol. 2020 Nov 5;11:598877. doi: 10.3389/fimmu.2020.598877. eCollection 2020.
3
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.

本文引用的文献

1
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.阿维鲁单抗联合阿昔替尼与舒尼替尼治疗晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.
2
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.派姆单抗联合阿昔替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.
3
Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma.晚期肾细胞癌患者不断演变的全身治疗格局
二线治疗转移性肾细胞癌患者：意大利多中心真实世界 SAX 研究最终结果。
J Transl Med. 2019 Aug 29;17(1):296. doi: 10.1186/s12967-019-2047-4.
J Clin Oncol. 2018 Oct 29:JCO2018790253. doi: 10.1200/JCO.2018.79.0253.
4
Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma.贝伐单抗与免疫检查点抑制剂联合用于肾细胞癌
Cancer J. 2018 Jul/Aug;24(4):171-179. doi: 10.1097/PPO.0000000000000323.
5
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.阿替利珠单抗单药或联合贝伐珠单抗与舒尼替尼治疗肾细胞癌的临床活性和分子相关性。
Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4.
6
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
7
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
8
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.利用抗血管生成药物增强癌症免疫治疗：机遇与挑战。
Nat Rev Clin Oncol. 2018 May;15(5):325-340. doi: 10.1038/nrclinonc.2018.29. Epub 2018 Mar 6.
9
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.阿昔替尼联合帕博利珠单抗治疗晚期肾细胞癌患者的 1b 期非随机、开放标签、剂量发现和剂量扩展研究。
Lancet Oncol. 2018 Mar;19(3):405-415. doi: 10.1016/S1470-2045(18)30081-0. Epub 2018 Feb 10.
10
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.联合癌症疗法可通过患者间的个体差异产生疗效，而无需药物相加作用或协同作用。
Cell. 2017 Dec 14;171(7):1678-1691.e13. doi: 10.1016/j.cell.2017.11.009.